PDF(Pubmed)
Abstract：
UNASSIGNED: The aim of this study was to better understand the efficacy of various drugs, such as glucocorticoids and anti-vascular endothelial growth factors (VEGF), in the treatment of diabetic macular edema (DME), and to evaluate various clinical treatment regimens consisting of different therapeutic measures.
UNASSIGNED: This study included randomized controlled trials up to February 2023 comparing the efficacy of corticosteroid-related therapy and anti-VEGF therapy. PubMed, the Cochrane Library, and Embase were searched, and the quality of the studies was carefully assessed. Finally, 39 studies were included.
UNASSIGNED: Results at 3-month followup showed that intravitreal injection of bevacizumab (IVB) + triamcinolone acetonide (TA) was the most beneficial in improving best-corrected visual acuity and reducing the thickness of macular edema in the center of the retina in patients with DME. Results at 6-month follow-up showed that intravitreal dexamethasone (DEX) was the most effective in improving patients\' bestcorrected visual acuity and reducing the thickness of central macular edema.
UNASSIGNED: Overall, IVB+TA was beneficial in improving best-corrected visual acuity and reducing central macular edema thickness over a 3-month follow-up period, while DEX implants had a better therapeutic effect than anti-VEGF agents at 6 months, especially the patients with severe macular edema and visual acuity impaired.
UNASSIGNED: https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=397100, identifier CRD42023397100.
UNASSIGNED: This study included randomized controlled trials up to February 2023 comparing the efficacy of corticosteroid-related therapy and anti-VEGF therapy. PubMed, the Cochrane Library, and Embase were searched, and the quality of the studies was carefully assessed. Finally, 39 studies were included.
UNASSIGNED: Results at 3-month followup showed that intravitreal injection of bevacizumab (IVB) + triamcinolone acetonide (TA) was the most beneficial in improving best-corrected visual acuity and reducing the thickness of macular edema in the center of the retina in patients with DME. Results at 6-month follow-up showed that intravitreal dexamethasone (DEX) was the most effective in improving patients\' bestcorrected visual acuity and reducing the thickness of central macular edema.
UNASSIGNED: Overall, IVB+TA was beneficial in improving best-corrected visual acuity and reducing central macular edema thickness over a 3-month follow-up period, while DEX implants had a better therapeutic effect than anti-VEGF agents at 6 months, especially the patients with severe macular edema and visual acuity impaired.
UNASSIGNED: https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=397100, identifier CRD42023397100.
摘要：
■这项研究的目的是更好地了解各种药物的疗效，如糖皮质激素和抗血管内皮生长因子（VEGF），在糖尿病性黄斑水肿（DME）的治疗中，并评估由不同治疗措施组成的各种临床治疗方案。
■这项研究包括截至2023年2月的随机对照试验，比较了皮质类固醇相关治疗和抗VEGF治疗的疗效。PubMed,Cochrane图书馆,Embase被搜查了,并仔细评估了研究的质量.最后,共纳入39项研究。
■3个月随访结果显示，玻璃体内注射贝伐单抗(IVB)+曲安奈德(TA)对改善DME患者最佳矫正视力和减少视网膜中央黄斑水肿厚度最有益。6个月随访结果显示，玻璃体腔注射地塞米松（DEX）对改善患者最佳矫正视力和减少黄斑中心性水肿厚度最有效。
■总的来说，IVB+TA在3个月的随访期内有利于改善最佳矫正视力和减少黄斑中心性水肿厚度。而DEX植入物在6个月时比抗VEGF药物具有更好的治疗效果，尤其是严重黄斑水肿和视力受损的患者。
■https://www.crd.约克。AC.uk/PROSPERO/display_record。php?RecordID=397100，标识符CRD42023397100。
■这项研究包括截至2023年2月的随机对照试验，比较了皮质类固醇相关治疗和抗VEGF治疗的疗效。PubMed,Cochrane图书馆,Embase被搜查了,并仔细评估了研究的质量.最后,共纳入39项研究。
■3个月随访结果显示，玻璃体内注射贝伐单抗(IVB)+曲安奈德(TA)对改善DME患者最佳矫正视力和减少视网膜中央黄斑水肿厚度最有益。6个月随访结果显示，玻璃体腔注射地塞米松（DEX）对改善患者最佳矫正视力和减少黄斑中心性水肿厚度最有效。
■总的来说，IVB+TA在3个月的随访期内有利于改善最佳矫正视力和减少黄斑中心性水肿厚度。而DEX植入物在6个月时比抗VEGF药物具有更好的治疗效果，尤其是严重黄斑水肿和视力受损的患者。
■https://www.crd.约克。AC.uk/PROSPERO/display_record。php?RecordID=397100，标识符CRD42023397100。
